How hormones regulate mood
Estrogen. Estrogen modulates serotonin, dopamine, and norepinephrine — the primary neurotransmitter systems involved in mood regulation, reward, and motivation. Its decline during perimenopause is directly associated with increased anxiety, irritability, tearfulness, and depression symptoms in women who had no prior history of mood disorders. This is not coincidence. It is mechanism.
Progesterone. Progesterone and its neurosteroid metabolite allopregnanolone modulate GABA-A receptors — the primary inhibitory system in the brain. Progesterone decline produces anxiety, difficulty calming down, and sleep-disrupting rumination that mimics anxiety disorder.
Testosterone. Testosterone affects motivation, drive, confidence, and competitive engagement in both sexes. Its decline — in men and women — produces a specific mood pattern: not sadness exactly, but flatness. Reduced interest. Lower tolerance for discomfort. Diminished initiative.
Cortisol chronicity. Sustained elevated cortisol produces hippocampal changes over time that directly increase anxiety, impair stress tolerance, and reduce emotional resilience. The HPA axis dysregulation that underlies adrenal fatigue is also the mechanism underlying chronic anxiety and mood instability in stressed individuals.
Thyroid dysfunction. The relationship between thyroid function and mood is bidirectional and well-established. Hypothyroidism produces depression-like symptoms — low energy, cognitive slowing, anhedonia, emotional withdrawal. Hyperthyroid states produce anxiety and emotional lability. Subclinical thyroid dysfunction can produce mood symptoms without meeting diagnostic thresholds on standard screening.
Why this does not always respond to antidepressants
Antidepressants address serotonin and norepinephrine signaling. They do not address estrogen deficiency, progesterone decline, testosterone deficiency, or thyroid dysfunction. When mood symptoms are driven by these mechanisms, antidepressants produce partial response at best — which is consistent with the clinical experience many mid-life patients report. This is not an argument against antidepressants. They are appropriate for primary depressive and anxiety disorders. It is an argument for completing the hormonal evaluation before concluding that the mood presentation is primarily psychiatric.
The clinical approach at Revitalize
Mood evaluation at Revitalize occurs in the context of a complete hormonal and metabolic assessment. The clinical history includes the timeline of mood change relative to hormonal transitions, medication history, sleep quality, and life context. The lab panel covers estradiol, progesterone, testosterone, thyroid function, cortisol patterns, and inflammatory markers. The intervention is built from what that data shows.